FOXP3 and cancer: Fig 8A presents the spatial distribution of all subtypes of cancer cells, CD8+ T cells, FoxP3+ T cells, and MDSCs in a section of a tumor slice 6 months after the initial diameter condition is met, with 3 mg/kg nivolumab administered every two weeks.